TY - JOUR
T1 - Locoregional management of hepatocellular carcinoma
T2 - Surgical and ablation therapies
AU - Rust, C.
AU - Gores, G. J.
N1 - Funding Information:
This work was supported by grants from the National Institute of Health (DK 41876), the Gainey Foundation, the Mayo Foundation (to GJG), and the Deutsche Forschungsgemeinschaft (to CR)
PY - 2001
Y1 - 2001
N2 - The selection of an appropriate treatment strategy for patients with HCC depends on careful tumor staging and assessment of the underlying liver disease (Fig. 5). All patients with localized HCC (involvement of one single lobe, no vascular invasion or extrahepatic disease) should be evaluated for the potentially curative therapeutic options of partial hepatectomy or OLT. Candidates for partial hepatectomy must have no liver disease or Child's A cirrhosis, normal portal pressure, and normal serum bilirubin. For patients not meeting these criteria, OLT should be considered if there is a solitary lesion smaller than 5 cm in diameter or fewer than three lesions smaller than 3 cm. Local ablative therapies such as PEI, RFA, and TACE offer palliation for patients for whom surgical approaches are contraindicated. Percutaneous alcohol injection and RFA are minimally invasive and can be used on an outpatient basis, usually for tumor nodules smaller than 3 cm. When these therapies are used for small tumors, the survival rates can be similar to those achieved by partial hepatectomy. Transcatheter arterial chemoembolization may be used as an interim treatment for patients waiting for OLT. Although TACE is often used for the palliation of large tumors, significant survival benefits have not yet been demonstrated for this indication.
AB - The selection of an appropriate treatment strategy for patients with HCC depends on careful tumor staging and assessment of the underlying liver disease (Fig. 5). All patients with localized HCC (involvement of one single lobe, no vascular invasion or extrahepatic disease) should be evaluated for the potentially curative therapeutic options of partial hepatectomy or OLT. Candidates for partial hepatectomy must have no liver disease or Child's A cirrhosis, normal portal pressure, and normal serum bilirubin. For patients not meeting these criteria, OLT should be considered if there is a solitary lesion smaller than 5 cm in diameter or fewer than three lesions smaller than 3 cm. Local ablative therapies such as PEI, RFA, and TACE offer palliation for patients for whom surgical approaches are contraindicated. Percutaneous alcohol injection and RFA are minimally invasive and can be used on an outpatient basis, usually for tumor nodules smaller than 3 cm. When these therapies are used for small tumors, the survival rates can be similar to those achieved by partial hepatectomy. Transcatheter arterial chemoembolization may be used as an interim treatment for patients waiting for OLT. Although TACE is often used for the palliation of large tumors, significant survival benefits have not yet been demonstrated for this indication.
UR - http://www.scopus.com/inward/record.url?scp=0035142168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035142168&partnerID=8YFLogxK
U2 - 10.1016/S1089-3261(05)70159-8
DO - 10.1016/S1089-3261(05)70159-8
M3 - Article
C2 - 11218913
AN - SCOPUS:0035142168
SN - 1089-3261
VL - 5
SP - 161
EP - 173
JO - Clinics in liver disease
JF - Clinics in liver disease
IS - 1
ER -